Restricted accessResearch articleFirst published online 2016-5
Intrathecal drug delivery for the management of pain and spasticity in adults: an executive summary of the British Pain Society’s recommendations for best clinical practice
This article provides a summary of the updated British Pain Society Guidance on Intrathecal Drug Delivery for the management of pain and spasticity in adults. We aim to highlight the areas of the guidance that have been updated and to provide a concise summary.
RaphaelJHDuarteRVSouthallJL. Randomised, double-blind controlled trial by dose reduction of implanted intrathecal morphine delivery in chronic non-cancer pain. BMJ Open2013; 3(7): e003061.
2.
SmithTJStaatsPSDeerT. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol2002; 20(19): 4040–4049.
3.
CoffeyRJOwensMLBrosteSK. Mortality associated with implantation and management of intrathecal opioid drug infusion systems to treat noncancer pain. Anesthesiology2009; 111(4): 881–891.
4.
FollettKANaumannCP. A prospective study of catheter-related complications of intrathecal drug delivery systems. J Pain Symptom Manage2000; 19(3): 209–215.
5.
DuarteRVRaphaelJHSparkesE. Long-term intrathecal drug administration for chronic non-malignant pain. J Neurosurg Anesthesiol2012; 24(1): 63–70.
6.
DeerTRLevyRPragerJ. Polyanalgesic Consensus Conference–2012: recommendations to reduce morbidity and mortality in intrathecal drug delivery in the treatment of chronic pain. Neuromodulation2012; 15(5): 467–482.
7.
TurnerJASearsJMLoeserJD. Programmable intrathecal opioid delivery systems for chronic noncancer pain: a systematic review of effectiveness and complications. Clin J Pain2007; 23(2): 180–195.
